Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Kyverna Therapeutics Stock Up 4.8 %

Shares of KYTX stock opened at $2.38 on Monday. The firm has a 50 day moving average of $2.95 and a 200-day moving average of $4.29. Kyverna Therapeutics has a 52 week low of $2.20 and a 52 week high of $25.98.

Institutional Investors Weigh In On Kyverna Therapeutics

A hedge fund recently raised its stake in Kyverna Therapeutics stock. Bank of America Corp DE lifted its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 41.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,788 shares of the company’s stock after purchasing an additional 6,400 shares during the quarter. Bank of America Corp DE owned about 0.05% of Kyverna Therapeutics worth $81,000 at the end of the most recent reporting period. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.